Intrinsic indicators for specimen degradation

Laboratory Investigation

Volumn 93, Issue 2, 2013, Pages 242-253

  Li, Jie ^a   Kil, Catherine ^a   Considine, Kelly ^a   Smarkucki, Bartosz ^a   Stankewich, Michael C ^a   Balgley, Brian ^b   Vortmeyer, Alexander O ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 6564 Loisdale Court   (United States)

Author keywords

alpha II spectrin; degradation; indicator; proteomics; specimen

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; AUTOPSY; CELL LINE; COLD ISCHEMIA; FLUORESCENCE ANALYSIS; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOELECTRIC POINT; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; QUALITY CONTROL; ROOM TEMPERATURE; TISSUE DEGENERATION; WESTERN BLOTTING;

EID: 84873868189     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.164     Document Type: Article

References (66)

1. Mann GB, Fahey VD, Feleppa F, et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005;23:5148-5154.
2. Chang JW, Chou CL, Huang SF, et al. Erlotinib response of EGFRmutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer 2007;58:414-417.
3. Loi S, Symmans WF, Bartlett JM, et al. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncol 2012;12:1162-1168.
4. Anagnostou VK, Welsh AW, Giltnane JM, et al. Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev 2010;19:982-991.
5. Bai Y, Tolles J, Cheng H, et al. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest 2011;91:1253-1261.
6. Tolles J, Bai Y, Baquero M, et al. Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Res 2011;13:R51.
7. Zhou C, Byard RW. Factors and processes causing accelerated decomposition in human cadavers-An overview. J Forensic Leg Med 2011;18:6-9.
8. Mann RW, Bass WM, Meadows L. Time since death and decomposition of the human body: variables and observations in case and experimental field studies. J Forensic Sci 1990;35:103-111.
9. Vass AA, Barshick SA, Sega G, et al. Decomposition chemistry of human remains: a new methodology for determining the postmortem interval. J Forensic Sci 2002;47:542-553.
10. Lee Goff M. Early post-mortem changes and stages of decomposition in exposed cadavers. Exp Appl Acarol 2009;49:21-36.
11. Szathmary SC, von Tamaska L, Steigel A. [Postmortem decomposition of neutral lipids. Use of modern methods of analysis (HPLC, capillary GC, GC-MS and NMR) in adipocere formation]. Z Rechtsmed 1985; 94:273-287.
12. Moreno LI, Mills D, Fetscher J, et al. The application of amplicon length heterogeneity PCR (LH-PCR) for monitoring the dynamics of soil microbial communities associated with cadaver decomposition. J Microbiol Methods 2011;84:388-393.
13. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002;161:1961-1971.
14. Espina V, Edmiston KH, Heiby M, et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008;7:1998-2018.
15. Jung K, Lein M, Brux B, et al. Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions. Clin Chem Lab Med 2000;38:1271-1275.
16. Tammen H. Specimen collection and handling: standardization of blood sample collection. Methods Mol Biol 2008;428:35-42.
17. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
18. Chin JL, Srigley J, Mayhew LA, et al. Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management: evidentiary base. Can Urol Assoc J 2012;4:13-25.
19. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol 2012;29:e458.
20. Park NJ, Yu T, Nabili V, et al. RNAprotect saliva: an optimal roomtemperature stabilization reagent for the salivary transcriptome. Clin Chem 2006;52:2303-2304.
21. Pinhel IF, Macneill FA, Hills MJ, et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 2010;12:R76.
22. De Cecco L, Musella V, Veneroni S, et al. Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer 2009;9:409.
23. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-1141.
24. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-1333.
25. Bartlett JM, Starczynski J, Atkey N, et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol 2012;64:649-653.
26. Moatamed NA, Nanjangud G, Pucci R, et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol 2012;136:754-761.
27. Huang Y, Laval SH, van Remoortere A, et al. AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J 2007;21:732-742.
28. Lee IH, Lim HJ, Yoon S, et al. Ahnak protein activates protein kinase C (PKC) through dissociation of the PKC-protein phosphatase 2A complex. J Biol Chem 2008;283:6312-6320.
29. De Matteis MA, Morrow JS. Spectrin tethers and mesh in the biosynthetic pathway. J Cell Sci 2000;113(Pt 13):2331-2343.
30. Sun HQ, Yamamoto M, Mejillano M, et al. Gelsolin, a multifunctional actin regulatory protein. J Biol Chem 1999;274:33179-33182.
31. Nekrasova OE, Mendez MG, Chernoivanenko IS, et al. Vimentin intermediate filaments modulate the motility of mitochondria. Mol Biol Cell 2011;22:2282-2289.
32. Gourlay CW, Carpp LN, Timpson P, et al. A role for the actin cytoskeleton in cell death and aging in yeast. J Cell Biol 2004;164:803-809.
33. Lawlor MW, Dechene ET, Roumm E, et al. Mutations of tropomyosin 3 (TPM3) are common and associated with type 1 myofiber hypotrophy in congenital fiber type disproportion. Hum Mutat 2010;31:176-183.
34. Procaccio V, Salazar G, Ono S, et al. A mutation of beta-actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia. Am J Hum Genet 2006;78:947-960.
35. Dutcher SK. The tubulin fraternity: alpha to eta. Curr Opin Cell Biol 2001;13:49-54.
36. Kaul G, Pattan G, Rafeequi T. Eukaryotic elongation factor-2 (eEF2): its regulation and peptide chain elongation. Cell Biochem Funct 2011; 29:227-234.
37. Srivastava S, Verschoor A, Frank J. Eukaryotic initiation factor 3 does not prevent association through physical blockage of the ribosomal subunit-subunit interface. J Mol Biol 1992;226:301-304.
38. Okuda M. The role of nucleophosmin in centrosome duplication. Oncogene 2002;21:6170-6174.
39. Choi YD, Grabowski PJ, Sharp PA, et al. Heterogeneous nuclear ribonucleoproteins: role in RNA splicing. Science 1986;231:1534-1539.
40. Gorlach M, Wittekind M, Beckman RA, et al. Interaction of the RNAbinding domain of the hnRNP C proteins with RNA. EMBO J 1992;11:3289-3295.
41. Lin S, Fu XD. SR proteins and related factors in alternative splicing. Adv Exp Med Biol 2007;623:107-122.
42. Spreter T, Pech M, Beatrix B. The crystal structure of archaeal nascent polypeptide-associated complex (NAC) reveals a unique fold and the presence of a ubiquitin-associated domain. J Biol Chem 2005; 280:15849-15854.
43. Kaiser BK, Yim D, Chow IT, et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007;447: 482-486.
44. Echeverri CJ, Paschal BM, Vaughan KT, et al. Molecular characterization of the 50-kD subunit of dynactin reveals function for the complex in chromosome alignment and spindle organization during mitosis. J Cell Biol 1996;132:617-633.
45. Poloz YO, O'Day DH. Determining time of death: temperature-dependent postmortem changes in calcineurin A, MARCKS, CaMKII, and protein phosphatase 2A in mouse. Int J Legal Med 2009;123:305-314.
46. Fan Z, Beresford PJ, Zhang D, et al. HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A. Mol Cell Biol 2002;22:2810-2820.
47. Fan Z, Beresford PJ, Oh DY, et al. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 2003;112:659-672.
48. Loiodice I, Alves A, Rabut G, et al. The entire Nup107-160 complex, including three new members, is targeted as one entity to kinetochores in mitosis. Mol Biol Cell 2004;15:3333-3344.
49. Sacksteder KA, Jones JM, South ST, et al. PEX19 binds multiple peroxisomal membrane proteins, is predominantly cytoplasmic, and is required for peroxisome membrane synthesis. J Cell Biol 2000;148: 931-944.
50. Pope AJ, Druhan L, Guzman JE, et al. Role of DDAH-1 in lipid peroxidation product-mediated inhibition of endothelial NO generation. Am J Physiol Cell Physiol 2007;293:C1679-C1686.
51. Bryantsev AL, Kurchashova SY, Golyshev SA, et al. Regulation of stressinduced intracellular sorting and chaperone function of Hsp27 (HspB1) in mammalian cells. Biochem J 2007;407:407-417.
52. Ramser J, Ahearn ME, Lenski C, et al. Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. Am J Hum Genet 2008;82:188-193.
53. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998;17:7151-7160.
54. Rivkin E, Kierszenbaum AL, Gil M, et al. Rnf19a, a ubiquitin protein ligase, and Psmc3, a component of the 26S proteasome, tether to the acrosome membranes and the head-tail coupling apparatus during rat spermatid development. Dev Dyn 2009;238:1851-1861.
55. Bennett V, Baines AJ. Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiol Rev 2001;81: 1353-1392.
56. Kizhatil K, Yoon W, Mohler PJ, et al. Ankyrin-G and beta2-spectrin collaborate in biogenesis of lateral membrane of human bronchial epithelial cells. J Biol Chem 2007;282:2029-2037.
57. Muresan V, Stankewich MC, Steffen W, et al. Dynactin-dependent, dynein-driven vesicle transport in the absence of membrane proteins: a role for spectrin and acidic phospholipids. Mol Cell 2001;7:173-183.
58. Nicolas G, Fournier CM, Galand C, et al. Tyrosine phosphorylation regulates alpha II spectrin cleavage by calpain. Mol Cell Biol 2002;22:3527-3536.
59. Cardali S, Maugeri R. Detection of alphaII-spectrin and breakdown products in humans after severe traumatic brain injury. J Neurosurg Sci 2006;50:25-31.
60. Knoblach SM, Alroy DA, Nikolaeva M, et al. Caspase inhibitor z-DEVDfmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. J Cereb Blood Flow Metab 2004;24: 1119-1132.
61. Zhang Z, Larner SF, Liu MC, et al. Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis 2009;14:1289-1298.
62. Dutta S, Chiu YC, Probert AW, et al. Selective release of calpain produced alphalI-spectrin (alpha-fodrin) breakdown products by acute neuronal cell death. Biol Chem 2002;383:785-791.
63. Newcomb JK, Pike BR, Zhao X, et al. Concurrent assessment of calpain and caspase-3 activity by means of western blots of protease-specific spectrin breakdown products. Methods Mol Biol 2000;144:219-223.
64. Glantz SB, Cianci CD, Iyer R, et al. Sequential degradation of alphaII and betaII spectrin by calpain in glutamate or maitotoxin-stimulated cells. Biochemistry 2007;46:502-513.
65. Wang KK, Posmantur R, Nath R, et al. Simultaneous degradation of alphaII-and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem 1998;273:22490-22497.
66. Nakajima E, Hammond KB, Rosales JL, et al. Calpain, not caspase, is the causative protease for hypoxic damage in cultured monkey retinal cells. Invest Ophthalmol Vis Sci 2011;52:7059-7067.